This article is more than 5 years old. Information may no longer be current.

Anti-VEGF preceding vitrectomy may facilitate high-quality outcomes and reduce complications

Br J Ophthalmol. 2011;95(9):1216-1222

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

Intravitreal bevacizumab preceding vitrectomy may enable good outcomes for diabetic retinopathy, potentially aiding surgical maneuvers and reducing complications, a study found.

A comprehensive literature search identified six randomized, controlled trials and one comparative study that were used to compare vitrectomy alone in 142 eyes and vitrectomy with Avastin (bevacizumab, Genentech) pretreatment in 139 eyes.

Occurrence of intraoperative bleeding and frequency of endodiathermy were significantly lower in the bevacizumab pretreatment group (P < .01). Moreover, this group required less surgical time (P = .003), and postoperative outcomes showed that blood reabsorption also took less time (P = .04), incidence of recurrent vitreous hemorrhage was insignificantly less and final best corrected visual acuity was better (P = .003).

Limitations to this analysis included potential publication bias, a large disparity in the quality of included studies and the fact that studies were heterogeneous in terms of location, population, number of patients and basal condition.